Coherus Biosciences (NASDAQ:CHRS) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, dividends and analyst recommendations.
This table compares Coherus Biosciences and Organovo’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
93.3% of Coherus Biosciences shares are owned by institutional investors. Comparatively, 36.3% of Organovo shares are owned by institutional investors. 26.3% of Coherus Biosciences shares are owned by company insiders. Comparatively, 3.5% of Organovo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Coherus Biosciences and Organovo’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Coherus Biosciences||$1.56 million||468.36||-$238.17 million||($4.48)||-2.40|
|Organovo||$4.60 million||25.95||-$34.80 million||($0.32)||-3.22|
Organovo has higher revenue and earnings than Coherus Biosciences. Organovo is trading at a lower price-to-earnings ratio than Coherus Biosciences, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings and target prices for Coherus Biosciences and Organovo, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Coherus Biosciences currently has a consensus target price of $30.75, indicating a potential upside of 186.31%. Organovo has a consensus target price of $1.75, indicating a potential upside of 69.90%. Given Coherus Biosciences’ higher possible upside, equities research analysts clearly believe Coherus Biosciences is more favorable than Organovo.
Risk and Volatility
Coherus Biosciences has a beta of 3.68, suggesting that its stock price is 268% more volatile than the S&P 500. Comparatively, Organovo has a beta of 2.42, suggesting that its stock price is 142% more volatile than the S&P 500.
Coherus Biosciences beats Organovo on 8 of the 13 factors compared between the two stocks.
About Coherus Biosciences
Coherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis. It is also developing a pipeline of products in therapeutic areas, such as oncology, immunology, and ophthalmology comprising CHS-3351, a ranibizumab biosimilar; and CHS-2020, an aflibercept biosimilar, as well as CHS-131, a small molecule for multiple sclerosis. Coherus BioSciences, Inc. has license agreement with Selexis SA and Genentech, Inc. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Organovo Holdings, Inc., a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat a range of rare, life-threatening diseases. In addition, the company offers preclinical in vitro disease modeling platforms, including a range of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis conditions. Further, it involved in various programs to develop its NovoTissues transplantable tissues to address various serious unmet medical needs in adult and pediatric populations primarily focusing on liver disease. The company was founded in 2007 and is headquartered in San Diego, California.
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.